PC
AXDX

Polar Capital’s Accelerate Diagnostics AXDX Stock Holding History

Polar Capital’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-103,767
Closed -$23.3M – 255
2017
Q3 		$23.3M Buy
103,767
+23,270
+29% +$5.72M 0.26% 115
2017
Q2 		$22M Buy
+80,497
New +$21.8M 0.3% 115

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Polar Capital's AXDX Position: Q4 2017 in Review

Polar Capital sold out of Accelerate Diagnostics (AXDX) in Q4 2017, closing a stake of 103,767 shares — an estimated $23.3M sold.

Polar Capital first reported a position in AXDX in Q2 2017 and held it in 2 quarters. The position peaked at $23.3M in Q3 2017. 118 funds tracked by Wall St. Rank hold AXDX as of Q4 2017.

  • Polar Capital reported no remaining Accelerate Diagnostics position as of Q4 2017 after selling out during the quarter.
  • Polar Capital sold 103,767 Accelerate Diagnostics shares in Q4 2017, an estimated $23.3M.
  • Polar Capital first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 2 quarters.
  • Polar Capital's Accelerate Diagnostics position peaked at $23.3M in Q3 2017.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2017.

Based on Polar Capital's 13F filing for Q4 2017, filed 14 Feb 2018.